Sionna Therapeutics, Inc. (SION) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Company Overview - Sionna is focused on cystic fibrosis and aims to transform the standard of care in this area [3] - The company is targeting a specific protein called NBD1 and is pursuing a dual combination therapy approach [3] Market Opportunity - There is a significant unmet need in the cystic fibrosis market, which Sionna aims to address through its innovative therapies [3]